SRS purchases AbbeyMoor Medical temporary prostatic stent

4 November 2012 (Last Updated November 4th, 2012 18:30)

SRS Medical, a manufacturer of voiding dysfunction diagnostic products, has purchased AbbeyMoor Medical's Spanner temporary prostatic stent for an undisclosed sum.

SRS Medical, a manufacturer of voiding dysfunction diagnostic products, has purchased AbbeyMoor Medical's Spanner temporary prostatic stent for an undisclosed sum.

SRS Medical CEO Lee Brody said the Spanner complements the company's suite of urology products for the diagnosis and treatment of men with symptoms of bladder outlet obstruction.

"Along with our flagship CT3000 UroCuff exam, SRS continues to provide the urologist innovative tools for diagnosis and treatment in the office setting," Brody said.

Approved by the Food and Drug Administration (FDA) and the European Union, the Spanner stent is designed as an alternative to an indwelling Foley catheter.

"Approved by the Food and Drug Administration (FDA) and the European Union, the Spanner stent is designed as an alternative to an indwelling Foley catheter."

The Spanner, which can be inserted or removed in a physician's office without anesthesia or cystoscopy, enables patients to fill and empty the bladder normally, while significantly reducing post void residual.

Carolina Urologic Research Centre medical director Dr Neal Shore said in a comparative prior trial with an indwelling catheter, the Spanner demonstrated a statistically significant reduction in the rate of bacterial colonisation, thus reducing clinically significant urinary tract infections.

"The avoidance of an external catheter and the attendant drainage bag should also result in quality of life benefit when using the Spanner," Shore said.

Other clinical studies have shown that the Spanner stent safely improves urine flow rates and decreases the amount of urine left in the bladder, while published data further shows that the stent is well-tolerated by patients and is preferred to a urethral catheter.